Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Aug;67(8):e28358.
doi: 10.1002/pbc.28358. Epub 2020 May 29.

Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012-2017

Affiliations
Randomized Controlled Trial

Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012-2017

Carol M Kao et al. Pediatr Blood Cancer. 2020 Aug.

Abstract

Background: Data are limited on the burden of influenza and seasonal influenza vaccine effectiveness (VE) in children with sickle cell disease (SCD).

Methods: We used a prospectively collected clinical registry of SCD patients 6 months to 21 years of age to determine the influenza cases per 100 patient-years, vaccination rates, and a test-negative case-control study design to estimate influenza VE against medically attended laboratory-confirmed influenza infection. Influenza-positive cases were randomly matched to test-negative controls on age and influenza season in 1:1 ratio. We used adjusted logistic regression models to compare odds ratio (OR) of vaccination in cases to controls. We calculated VE as [100% × (1 - adjusted OR)] and computed 95% confidence intervals (CIs) around the estimate.

Results: There were 1037 children with SCD who were tested for influenza, 307 children (29.6%) had at least one influenza infection (338 infections, incidence rate 3.7 per 100 person-years; 95% CI, 3.4-4.1) and 56.2% of those tested received annual influenza vaccine. Overall VE pooled over five seasons was 22.3% (95% CI, -7.3% to 43.7%). Adjusted VE estimates ranged from 39.7% (95% CI, -70.1% to 78.6%) in 2015/2016 to -5.9% (95% CI, -88.4% to 40.4%) in the 2016/17 seasons. Influenza VE varied by age and was highest in children 1-5 years of age (66.6%; 95% CI, 30.3-84.0). Adjusted VE against acute chest syndrome during influenza infection was 39.4% (95% CI, -113.0 to 82.8%).

Conclusions: Influenza VE in patients with SCD varies by season and age. Multicenter prospective studies are needed to better establish and monitor influenza VE among children with SCD.

Keywords: influenza; sickle cell disease; test-negative; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Study enrollment and influenza case status, 2012–2017 *Each 12-month period starts on July, 1 and ends on June, 30 in next calendar year and includes one influenza season. **Influenza seasons were defined as October 1 to April 30 for the years: 2012–2013, 2013–2014, 2014–2015, 2015–2016, and 2016–2017 ***33 children had >1 infection at least 30 days apart (31 children with 2 infections, 2 children with 3 infections)

Similar articles

Cited by

References

    1. Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010; 55(3): 401–6. - PubMed
    1. Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics 2010; 125(2): 234–43. - PMC - PubMed
    1. Inusa B, Zuckerman M, Gadong N, et al. Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. Blood 2010; 115(11): 2329–30. - PubMed
    1. Caboot JB, Allen JL. Pulmonary complications of sickle cell disease in children. Curr Opin Pediatr 2008; 20(3): 279–87. - PubMed
    1. George A, Benton J, Pratt J, et al. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer 2011; 57(4): 648–53. - PMC - PubMed

Publication types

Substances